Literature DB >> 18754282

Action of progesterone receptor modulators on uterine leiomyomas.

N Ohara.   

Abstract

Novel progesterone receptor modulators (PRMs) have recently been demonstrated to be effective in the treatment of patients with symptomatic uterine leiomyomata. PRMs are shown to reduce leiomyoma size and improve leiomyoma-associated symptoms. However, the precise mechanisms underlying the action of PRMs remain to be elucidated. My co-workers and I have investigated in vitro action of PRMs in cultured leiomyoma cells and revealed that PRMs inhibit cell proliferation and induce apoptosis of leiomyoma cells. Moreover, our recent studies show that PRMs can modulate the metabolism of extracellular matrix proteins in cultured leiomyoma cells toward the collagenolysis. The update about an action of PRMs in uterine leiomyoma cells in vitro is described in this article.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18754282

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  4 in total

Review 1.  Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.

Authors:  Pasquapina Ciarmela; Md Soriful Islam; Fernando M Reis; Peter C Gray; Enrrico Bloise; Felice Petraglia; Wylie Vale; Mario Castellucci
Journal:  Hum Reprod Update       Date:  2011-07-25       Impact factor: 15.610

Review 2.  Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder.

Authors:  Nasser Chegini
Journal:  Semin Reprod Med       Date:  2010-04-22       Impact factor: 1.303

3.  Development of Primary Monolayer Cell Model and Organotypic Model of Uterine Leiomyoma.

Authors:  Natalia Shved; Anna Egorova; Natalia Osinovskaya; Anton Kiselev
Journal:  Methods Protoc       Date:  2022-02-06

4.  Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growth.

Authors:  Jeannine Bloch; Carsten Holzmann; Dirk Koczan; Burkhard Maria Helmke; Jörn Bullerdiek
Journal:  Oncotarget       Date:  2017-05-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.